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SUMMARY
Obesity is a major human health crisis that promotes
insulin resistance and, ultimately, type 2 diabetes.
The molecular mechanisms that mediate this
response occur across many highly complex biolog-
ical regulatory levels that are incompletely under-
stood. Here, we present a comprehensive molecular
systems biology study of hepatic responses to high-
fat feeding in mice. We interrogated diet-induced
epigenomic, transcriptomic, proteomic, and metab-
olomic alterations using high-throughput omic
methods and used a network modeling approach
to integrate these diverse molecular signals. Our
model indicated that disruption of hepatic architec-
ture and enhanced hepatocyte apoptosis are
among the numerous biological processes that
contribute to early liver dysfunction and low-grade
inflammation during the development of diet-
induced metabolic syndrome. We validated these
model findings with additional experiments on
mouse liver sections. In total, we present an integra-
tive systems biology study of diet-induced hepatic
insulin resistance that uncovered molecular features
promoting the development and maintenance of
metabolic disease.
INTRODUCTION
Human obesity is a major worldwide health crisis (Flegal et al.,
2013) that promotesmetabolic syndrome (characterized by insu-
lin resistance, hyperglycemia, and hypertension) (Lusis et al.,
2008), b-cell dysfunction, and, ultimately, type 2 diabetes
(Kahn et al., 2006). The liver is an insulin-sensitive organ that is
critical for the maintenance of normal glucose homeostasis
(Michael et al., 2000). Insulin promotes increased uptake of
glucose in peripheral tissues (primarily skeletal muscle) and re-
duces hepatic gluconeogenesis (DeFronzo et al., 1985). Insulin
resistance suppresses these normal regulatory mechanisms
and, thus, promotes hyperglycemia. Consumption of a high-fat
diet (HFD) causes insulin resistance, which prevents insulin-
mediated inhibition of hepatic gluconeogenesis (Pilkis and
Granner, 1992). Moreover, peripheral insulin resistance (e.g., in
adipose tissue) causes increased lipolysis that promotes hepatic
gluconeogenesis (Perry et al., 2015; Titchenell et al., 2015, 2016).
The critical role of the liver in glycemic regulation is particularly
highlighted by the widespread use of the drug metformin to treat
type 2 diabetes, which principally acts in the liver to inhibit gluco-
neogenesis and reduce plasma triglyceride levels (Viollet and
Foretz, 2013). Thus, understanding the molecular mechanisms
of hepatic insulin resistance may provide a basis for the design
of therapeutic interventions.
The intracellular pathways that promote and maintain insulin
resistance and type 2 diabetes are highly complex and still not
fully understood. Perplexingly, diabetics experience ‘‘selective
insulin resistance’’ whereby insulin fails to suppress hepatic
glucose production but still promotes hepatic lipogenesis
(Brown and Goldstein, 2008; Shimomura et al., 2000; Titchenell
et al., 2016). Surprisingly, triple-knockout Akt1/Akt2/Foxo1 and
double-knockout Insr/Foxo1mice still suppress hepatic glucose
production in response to insulin (Lu et al., 2012; Perry et al.,
2015; Titchenell et al., 2015). As a result, systems biology ap-
proaches are increasingly being recognized as vital to the study
of metabolic diseases (Zhao et al., 2015). Systems biology em-
braces the inherent complexities of disease and draws upon
the wealth of available knowledge from molecular biology and
biochemistry to facilitate comprehensive, multi-dimensional
analysis and modeling of disease-relevant systems and pro-
cesses (Kitano, 2002).
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Available omic technologies enable rapid and comprehensive
analysis of many biological regulatory levels. Epigenomic and
transcriptomic methodologies (e.g., chromatin immunoprecipi-
tation sequencing [ChIP-seq] and mRNA sequencing [mRNA-
seq]) rapidly profile full genomic regulatory and gene expression
landscapes (Metzker, 2010). Proteomic analysis via mass spec-
trometry is increasingly becoming more sensitive and compre-
hensive, allowing for detailed analysis of global and modified
proteomes (Azimifar et al., 2014). Metabolomics, the collective
study of small-molecule species, is now being used extensively
to identify new mechanisms and biomarkers of metabolic dis-
ease in both targeted and untargeted fashions (Dunn et al.,
2011).
Few studies, to date, have attempted to analyze and integrate
multiple types of omic data in the context of diet-induced meta-
bolic disease. Those that have used simple correlative statistics
(Miraldi et al., 2013; Oberbach et al., 2011), overlaid proteomic
and metabolomic data onto known pathways with genome-
scale metabolic reconstructions (Yizhak et al., 2010), or com-
bined transcriptomic and metabolomic data with known
pathway and regulatory data for analysis within local interaction
neighborhoods (Eckel-Mahan et al., 2013). By contrast, we inte-
grate matched multi-omic data into a tractable network model
that is not biased toward interactions occurring in well-estab-
lished signaling or metabolic pathways. Instead, we collate
diverse types of interactions from databases of literature-
curated and high-throughput data to build a large network of
physical associations. We then use advanced network optimiza-
tion methods to prune the possible interaction space to only the
most relevant connections that model the input data. Our results
are, thus, more interpretable and provide clearer directions for
follow-up studies.
We present a comprehensive integrative analysis of high-fat-
diet (HFD)-induced hepatic insulin resistance in the mouse liver.
We fed male C57BL/6J mice a 16-week HFD to induce obesity
and insulin resistance and compared these animals to normal
chow-diet (CD)-fed controls. We collected genome-wide epige-
nomic data using histone modification ChIP-seq to interrogate
active genomic regulatory regions, performed mRNA-seq to
quantify hepatic transcriptomes, utilized an untargeted shotgun
proteomic profiling methodology to quantify >6,000 hepatic pro-
teins, and quantified nearly 400 small molecules to interrogate
molecular responses to high-fat feeding. We identified genes,
proteins, and metabolites altered between CD and HFD and
jointly analyzed our epigenomic and transcriptomic data to pre-
dict transcriptional regulators that likely influence gene expres-
sion changes between the diets. We then developed a network
modeling approach based on the prize-collecting Steiner forest
(PCSF) algorithm (Tuncbag et al., 2013, 2016) to analyze all
the omic data in the context of known protein-protein and pro-
tein-metabolite interactions. For this purpose, we constructed
a vast interactome of such associations and developed compu-
tational methods to avoid biases from well-studied, highly
connected proteins and metabolites. The PCSF model revealed
a richly interconnected network of biological species and
processes perturbed by HFD that could be divided into func-
tional sub-networks. This analysis uncovered well-established
features of hepatic insulin resistance, including glucose, lipid,
and amino acid metabolism. Importantly, it also revealed
poorly characterized aspects of the condition, including hepato-
cellular injury, cell-cell interactions, extracellular matrix (ECM)
organization, and apoptosis. Finally, we validated several
network modeling predictions with additional experiments on
frozen liver sections from CD and HFD livers. We showed that
HFD feeding leads to disrupted hepatic architecture and tight
junctions, altered bile acid handling, and enhanced cellular
apoptosis.
RESULTS
High-Fat-Diet Feeding Induces Obesity and Insulin
Resistance in Mouse
We examined diet-induced obesity and insulin resistance by
feeding 8-week-old male C57BL/6J mice an HFD for 16 weeks
(Figure 1). Control mice were fed a standard chow diet (CD) for
the same 16-week period, and all animals were euthanized at
Figure 1. Overview of Systems Biology
Study of HFD-Induced Insulin Resistance
We fed 8-week-old male C57BL/6J mice a 16-
week standard laboratory chow diet (CD) or a
high-fat diet (HFD) to induce obesity and insulin
resistance. At 24 weeks, we sacrificed the mice
and extracted, flash froze, and pulverized their
livers. We used these tissue samples to assay
epigenomes, transcriptomes, proteomes, and
metabolomes. We then used mRNA-seq (differ-
ential genes) and histone modification ChIP-seq
(valleys within enriched peaks) data with known
DNA-binding motifs to infer active transcriptional
regulators. These regulators, along with differential
proteins andmetabolites, were used as input to the
prize-collecting Steiner forest (PCSF) algorithm to
uncover a network of interconnections among the
data. ESI, electrospray ionization; GC-MS, gas
chromatography-mass spectrometry; LC-MS/MS,
liquid chromatography-tandem mass spectrom-
etry; TF, transcription factor.
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the 24-week time point. This model is particularly suited for the
study of human metabolic diseases, as HFD consumption by
mice induces complications consistent with the progression of
human metabolic syndrome (Collins et al., 2004). Indeed, we
found that HFD-fed mice exhibited obesity, hepatic steatosis,
hyperglycemia, insulin resistance, and glucose intolerance
compared with CD-fed mice (Figure S1).
Omic Datasets Demonstrate Wide-Ranging Effects of
HFD on Mouse Liver Biology
We collected an array of datasets using high-throughput omic
experimental methods to broadly capture the effects of HFD in
the liver (Figures 1 and 2). We used the information obtained
from analysis of these datasets to inform our subsequent inte-
grative network modeling efforts.
Epigenomics
We profiled the epigenomes of CD and HFD livers with histone
modification ChIP-seq experiments for H3K27Ac, which marks
active enhancers (Creyghton et al., 2010); H3K4me3, which
marks active and poised promoters (Santos-Rosa et al., 2002);
and H3K4me1, which marks active and poised enhancers
(Creyghton et al., 2010) (Figure 2, top panels). We tested for dif-
ferences in histone modification levels between the diets but
found few significant differential regions (<1%). Overall, these
data provide a comprehensive map of >22,000 active regulatory
regions, of which 89% map within ±20 kb of >14,000 expressed
liver genes.
Transcriptomics
We used mRNA-seq to identify 2,507 genes differentially ex-
pressed between CD and HFD livers. Of these, 1,572 genes
are upregulated, and 935 genes are downregulated in HFD livers
(Figure 2, bottom left; Figure S2A). Genes upregulated by HFD
are enriched in lipid metabolism (Aacs, Ldlr, and Srebf1) and
carbohydrate metabolism (Gck, Hk2, and Pfkl), while genes
downregulated by HFD are enriched in amino-acid catabolism
(Arg1, Gldc, Got1, and Hdc) and small-molecule catabolism
(Aadat, Aass, Cps1, Csad). Shared biological enrichments be-
tween the two classes of genes include carboxylic acid and
oxoacid metabolism. We also performed TaqMan assays on
additional CD and HFD samples (8 or more livers per condition)
to further test for evidence of immune cell infiltration in HFD livers
(as observed in our mRNA-seq results) (Figure S3). We found up-
regulation of Cd3e (T cells), Cd11c (dendritic cells/monocytes/
macrophages), Emr1 (monocytes/macrophages), and Nos2
(M2-like macrophages), together with downregulation of Arg1
(M2-like macrophages). These results suggest that immune
cell infiltration, indeed, plays a role in promoting and maintaining
the insulin-resistant state of HFD mice.
Proteomics
We used mass spectrometry (Zhou et al., 2013) to quantify CD
and HFD liver global proteomes, identifying 51,689 unique pep-
tides that mapped to 6,384 unique proteins. We used a weighted
least-squares regression procedure to find 362 differentially ex-
pressed proteins, with 189 upregulated and 173 downregulated
in HFD livers (Figure 2, bottom middle; Figure S2B). Proteins up-
regulated by HFD are uniquely enriched in fatty acid b-oxidation
(CROT, ECI1, and HADH), fatty acid transport (CD36, FABP1,
and FABP2) and carbohydrate biosynthesis (FBP1, GBE1,
GCK, and GYS2), while the proteins downregulated by HFD
are uniquely enriched in cholesterol biosynthesis (CYP51,
DHCR7, FDPS, and IDI1) and the urea cycle (CPS1, NAGS,
andOTC). Both sets of proteins are enriched in amino acid meta-
bolism, carboxylic acid metabolism, and oxidation-reduction
processes (Data S1).
Metabolomics
We obtained metabolomic measurements by mass spectrom-
etry of 381 metabolites in CD and HFD livers (Figure 2, bottom
right; Figure S2C); 96 metabolites are significantly different be-
tween the two diets, with 43 upregulated and 53 downregulated
by HFD. These metabolites include amino acids (11 upregulated
and 22 downregulated by HFD), lipids (11 upregulated and 21
downregulated by HFD), carbohydrates (10 upregulated and 1
downregulated by HFD), and peptides (2 upregulated and 2
Figure 2. HFD Induces Perturbations to Hepatic Omic Levels
(Top panels) Smoothed read density profiles in ±2-kb windows around the
union of all identified enrichment regions (22,974 total) for histone marks
H3K27Ac, H3K4me3, and H3K4me1 from CD liver samples. The mappings on
the left are with respect to the closest RefSeq gene start site: promoter (±2 kb
to start site); intragenic, 20 kb (within 20 kb upstream), +20 kb (within 20 kb
downstream), and intergenic (>20 kb away from nearest gene). (Lower panels)
We found 2,507 genes (n = 3 for CD and HFD), 362 global proteins (n = 4 for CD
and HFD), and 96 metabolites (n = 6 for CD and HFD) perturbed by HFD
consumption. Clustergrams show individual Z-scored values for species from
CD and HFD replicates. Only the most significantly changing peptide is shown
as a representative for each of the differential global proteins, though full
statistics were performed on all peptides.
See also Figures S1, S2, S3, and S4.
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downregulated by HFD) (Data S2). We also observed expected
increases in the levels of glucose and other carbohydrate mole-
cules, as hyperglycemia is a well-established feature of hepatic
insulin resistance.
Overall changes in gene and protein expression induced by
HFD consumption are only weakly to moderately correlated
(r = 0.2–0.4), even when we restrict our analyses to genes and
proteins that were called significantly different between both
conditions (Figures S4A and S4B). This modest correlation is
generally consistent with other systems (Schwanha¨usser et al.,
2011) and is also consistent with prior observations from CD
and HFD mouse livers on a smaller, targeted set of 200
matched species (Wu et al., 2014). We also observed specific
biological processes that are enriched in the set of differential
mRNAs but not in the set of differential proteins (and vice
versa). For example, proteins upregulated by HFD are uniquely
enriched in fatty acid b-oxidation and carboxylic acid catabo-
lism (Figure S4C). These comparisons demonstrate how individ-
ual omic datasets can highlight different aspects of disease
processes.
Epigenomic and Transcriptomic Dataset Integration
Uncovers Transcriptional Regulators Influencing
Differential Gene Expression
We collected epigenomic and transcriptomic data with the goal
of uncovering changes in transcriptional regulation between CD
and HFD livers. To reconstruct this transcriptional regulatory
network, we inferred the genomic binding locations of potential
transcriptional regulators using our ChIP-seq datasets and
DNA-binding motif data from TRANSFAC (Wingender et al.,
1996). As we found little evidence for changes in these histone
modifications between diets, we used the set of significant
ChIP-seq regions in CD livers for our analyses. We searched
each dataset for histone ‘‘valleys,’’ or regions between peaks
of local modification enrichment where histones are depleted
and where regulators likely bind (Figure 3A) (Ramsey et al.,
2010; Wamstad et al., 2012). We merged these discovered val-
leys into one set of 123,974 total loci and scanned the underlying
genomic sequences for matches to a set of 1,588 DNA-binding
motifs that map to at least one human or mouse transcriptional
regulator (Figure 3B). For each regulator (motif) and each differ-
entially expressed gene, a transcription factor affinity (TFA) score
was derived as a distance-weighted sum of individual motif
enrichment scores in regions near the gene’s annotated tran-
scription start site. We then used the linear regression of each
motif’s TFA scores against the expression levels of all the differ-
entially expressed genes and took significant regression coeffi-
cients (false discovery rate [FDR] < 0.01) as evidence for active
regulators (Figures 3C and 3D).
In total, we identified 358 significant DNA-binding motifs that
mapped to 272 unique transcriptional regulatory proteins (Data
S3), including known liver-enriched transcription factors such
as hepatic nuclear factors 1a, 1b, and 4a; retinoid X receptors
a and b; peroxisome proliferator-activated receptor a; and
C/EBPa (Schrem et al., 2002, 2004). We also found strong
enrichment for nuclear factor I proteins (A, B, C, and X), SOX4,
FOXO1, and the vitamin D receptor (VDR). These significant fac-
tors served as the core transcriptional regulatory data that we
incorporated into our network models.
Prize-Collecting Steiner Forest Model Integrates
Multiple Omic Datasets
Each type of omic data provides a glimpse into the effect of HFD
on a particular regulatory level. To obtain a more comprehensive
view of the data, we expanded upon an established network
modeling algorithm called the prize-collecting Steiner forest
(PCSF) (Tuncbag et al., 2013, 2016). We built a combined
protein-protein and protein-metabolite interactome from the
A B
C D
Figure 3. Motif Regression Procedure Iden-
tifies Transcriptional Regulators
(A) We extracted read density profiles for signifi-
cantly enriched histone modification levels,
smoothed the profiles, and scanned for ‘‘histone
valleys,’’ or regions of local signal depletion (an
H3K27Ac enrichment region is shown here as an
example). TSS, transcription start site.
(B) For each valley, we scanned the underlying
genomic sequence formatches to a library of DNA-
binding factor motifs. Against each differential
gene, we computed a transcription factor affinity
(TFA) score for all motifs as a distance-weighted
sum of individual match scores.
(C) For each motif, we used linear regression to
predict gene expression levels from the motif TFA
scores.
(D) This procedure found 358 significant motifs that
map to 272 regulatory proteins; select results are
shown in the table.
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iRefIndex (v.13) database (Razick et al., 2008) for protein-protein
interactions and obtained protein-metabolite interactions from
the Human Metabolome Database (HMDB; v.3.6) (Wishart
et al., 2013) and the human metabolic reconstruction Recon 2
(v.3) (Thiele et al., 2013). To account for differences in reliability
of the various types of interactions, we assigned to each an
‘‘edge cost’’ that scaled inversely with our confidence in the
interaction (see Experimental Procedures for details). We used
this interaction network and the omic data as input to the
PCSF algorithm to identify interactions that connect the omic
data (Figure S5).
As part of the PCSF approach, omic results (e.g., differential
proteins) are assigned prizes (e.g., as log2 fold changes), and
the algorithm attempts to maximize the inclusion of these prize
nodes while avoiding low-confidence edges, which have high
edge costs. Thus, the algorithm is not constrained to include
all data in the final network but, at the same time, is capable of
introducing species not present in the original set of data. These
interactome-derived species are called ‘‘Steiner’’ nodes and are
included when necessary to create connections between the
data. We also implemented a method that assigns ‘‘negative pri-
zes’’ to interactome nodes with many interactions. These highly
connected species, or ‘‘hubs,’’ have a high likelihood of appear-
ing in network models run with almost any input data (e.g., ubiq-
uitin or water). Negative prizes discourage the algorithm from
using such nodes in the PCSF solution and allow for more spe-
cific interactions to explain the data (Figures S6A and S6B).
We used as input data—or ‘‘terminals’’ in PCSF parlance—83
differential metabolites, 329 differential proteins, and the 272
transcriptional regulators identified by our motif regression anal-
ysis (Data S4). We generated and merged multiple solutions by
running the algorithm on the same data multiple times with
random noise added to the edge costs. This procedure pro-
duced a richer set of possible connections explaining the data
and enabled the assessment of network components’ robust-
ness. We also assessed node specificity to hepatic insulin resis-
tance by comparing how many times each node appears in
networks generated with random input data (i.e., random inter-
actome nodes that match the degree distribution of the real input
data).
The full PCSF solution (Figure 4; Data S5) includes 907 species
connected by 2,365 interactions (see also Table 1). We found
that the vast majority of nodes included in the final network are
very specific to our system (Figure S6C). To increase interpret-
ability of the network model, we identified smaller sub-networks
and performed gene, small-molecule, and pathway enrichment
analyses on these. We computed rank scores for these sub-net-
works according to their prize densities (the sum of prizes multi-
plied by the fractional size of the sub-network; Figure S7).
Among the top ranked sub-networks are those enriched for
amino acid and pyruvate metabolism, fatty acid oxidation,
apoptosis, transcription, ECM, and bile acid metabolism. Addi-
tionally, we devised a scheme to rank interactome-derived
Steiner nodes by their likely importance in the model according
to several features, including the robustness and specificity of
nodes. We used a weighted summation of scores based on
these features to perform this ranking (see Experimental Proced-
ures for details).
The PCSF Model Introduces Species with Known
Relevance to Metabolic Disease
We developed an automated strategy to identify network nodes
that have not been previously reported as associated with insulin
resistance and related complications. For this purpose, we used
the DisGeNET database (Pin˜ero et al., 2015), which collates
gene-disease information from public data as well as from liter-
ature via natural language processing, to determine which of
the predicted molecules introduced by the PCSF into the
network (Steiner nodes) are known to be associated with
obesity, insulin resistance, and/or type 2 diabetes. Of 394 Steiner
proteins, 121 (30%) possess some known disease link accord-
ing to DisGeNET (Data S4). Some examples include: clusterin
(CLU), in which polymorphisms are associated with type 2 dia-
betes (Daimon et al., 2011) and where knockout in C57BL/6J
mice exacerbates HFD-induced insulin resistance (Kwon et al.,
2014); L-arginine:glycine amidinotransferase (GATM, a.k.a.
AGAT), where knockout in C57BL/6J mice depletes creatine, en-
hances glucose tolerance, and protects from diet-induced
obesity (Choe et al., 2013); and nuclear receptor co-activator 1
(NCOA1, a.k.a. SRC-1), depletion of which can result in
increased glucose uptake, enhanced insulin sensitivity, and
resistance to age-associated obesity and glucose intolerance
(Wang et al., 2012). A literature review revealed additional Steiner
nodes with known relevance to disease, including themetabolite
glyoxylic acid, which has been characterized as amarkermetab-
olite for type 2 diabetes (Nikiforova et al., 2014). Thus, our model
incorporates many predicted nodes with known relevance to
these conditions, though many are not well-established actors
in these contexts.
The PCSF Model Identifies Biological Features of
Obesity-Induced Hepatic Insulin Resistance
Among the 20 sub-networks we identified from the full PCSF
model are networks enriched in glucose and glycogen meta-
bolism (sub-network 2), amino acid metabolism (sub-network 1),
fatty acid and lipid oxidation (sub-network 7), transcriptional
regulation (sub-network 11), and bile acid metabolism (sub-
network 13). These sub-networks all describe well-established
aspects of hepatic insulin resistance (Data S5 and S6). Specific
details for some of the biological mechanisms contained in these
sub-networks are included in the Supplemental Information.
Importantly, we also identified sub-networks enriched in bio-
logical processes not typically associated with hepatic insulin
resistance. One such sub-network is enriched in ECM organiza-
tional and structural proteins (sub-network 10; Figure 5). Proteins
associated with the ECM in this sub-network include collagens
1A1, 1A2, and 6A1 (COL1A1/1A2/6A1), as well as endoglin
(ENG), fibronectin 1 (FN1), intergrin a5 (ITGA5), and the trans-
forming growth factor b (TGF-b) receptor 1 (TGFB1). At the cen-
ter of this sub-network is FN1, which connects, among other
nodes, most of the collagen proteins and ITGA5. Both ENG
and TGFBR1 are predicted Steiner nodes connected through
ITGA5. Several Steiner nodes in this sub-network rank very
highly by our criteria, including CD79A, 50-30 exoribonuclease 1
(XRN1), and CLU.
Changes to the hepatic ECM may also implicate altered cell-
cell communication between hepatocytes in response to ECM
Cell Reports 21, 3317–3328, December 12, 2017 3321
and liver architectural disruption. Indeed, we found a sub-
network enriched in proteins related to cell-cell interactions
(sub-network 9; Figure 5). Included in this sub-network are the
proteins E-cadherin (CDH1), cadherin 5 (CDH5), junction plako-
globin (JUP), and vimentin (VIM). These enrichments strongly
suggest that changes to liver structure and the composition of
the ECM are relevant to hepatic insulin resistance.
We also identified a sub-network enriched in apoptotic pro-
cesses (sub-network 5; Figure 5). Terminal proteins involved in
apoptosis here include autophagy-related 5 (ATG5, a late-
apoptosis protein that interacts with FADD; Pyo et al., 2005),
BCL-2-associated transcription factor 1 (BCLAF1), and inter-
feron (IFN)-g-inducible protein 16 (IFI16). The majority of the
apoptosis-related proteins are predicted nodes, including
BCL2; BCL2L1; caspases 7, 9, and 10; FAS; the FAS-associated
death domain (FADD); and BAD. The model captures aspects of
the extrinsic apoptotic pathway, whereby the death-inducing
signaling complex composed of FAS, FADD, and pro-caspase 8
or -10 signals to downstream effectors (Wang et al., 2001), as
well as the intrinsic pathway, which involves the pro-apoptotic
Bcl-2 family member BAX and anti-apoptotic members BCL2
and BCL2L1 (Lee and Pervaiz, 2007). The model includes both
initiator (CASP8 and CASP10) and effector caspases (CASP7)
linked to these initiator proteins (Wang, 2014). Thus, our PCSF
model, overall, suggests a role for apoptosis in maintaining he-
patic insulin resistance.
ATOX1VAPB
HPX
GC ATP7B
MIS12
C3ATF4
HPMRPS15CLU
PRNP
THBS1
VKORC1
AMBP
RAB3B
CRCT1
CTSB
PLG
CCT5
ENG
TAB2
PTN
COL6A1
DNAJB11
IKBKAP
CSTA
CRP
TBPL1
SAMD8
CTSH
SM(d18:1/18:0)
RPLP1
DPP7
LRG1
ZWINT
LGALS9
LGALS8
CD79A
ITIH4
COL1A2
COL1A1
PIGR
FTL
XRN1
FN1
FGB
LRP2
C8B
FGG
CYP27A1
Dehydroepiandrosterone-sulfate
ACYP2 ACYP1
TGFBR1
ITGA5
RAP2A
CSTB
DHFR
CFH
PTCD3
GSTP1
GLUD1
SUPT7L
PON1
TGM2
HSP90B1
PARK2
UBAP2L
PI4K2A
BCL2L1
VDAC1
DAXX
BCAP31
EMD
PDCD4ARHGDIACASP9
BIRC3
DIABLO
SH3GL2
APAF1
RRAS
BCL2 IFI16
RARRES3
XIAP
UBE2L3
PSAP
SNCA
ATG5
SCAMP2
TCP1
ETS1
CASP7
BAK1
LAPTM5
DAZAP1
CRYAA
IFIH1
MAVS
Tiglylglycine
Acetylglycine
Suberylglycine
ITCH
FADD
CASP10 RNF41
TWF2
SNCAIP
UQCRC1
TMEM173GSTM3
BMF
COMMD10
BIRC2
UFD1L
COMMD1
MPC2
EDEM2
HAX1
UBXN7
RTN4
GRB7
HTRA2
BRWD3
PDXDC1
PAPSS2
PARP2ERC1
ARIH2
GBA
BAXWWP1
SPG20
BIRC6
BCLAF1
TTC39C
MTHFD2
THOP1
OAT
Thiamine-pyrophosphate
Flavin-Mononucleotide
Thiamine-triphosphate
SDHB
Fumaric-acid
Ornithine
OTC
FAH
IDH1
Guanidoacetic-acid
OGDH
SDHA
ASL OXCT1
NAGS
N-Acetyl-L-alanine
TIMM9
GLYAT
GLYATL1
N-Acetylglutamic-acid
BAAT
ACSL1
3a,7a-Dihydroxycoprostanic-acid
SLC27A2
3a,7a,12a-Trihydroxy-5b-cholestanoic-acid
TLN1
Eicosapentaenoic-acid
ABCB11
Alpha-Muricholic-acidArachidic-acid
3-Phosphoglyceric-acid
CES3
Taurocholic-acid
8,11,14-Eicosatrienoic-acid
CPS1
SUCLG2
Carbamoyl-phosphate
GSTZ1
SEC22B
Stearidonic-acid
TST
Glycocholic-acid
SLCO1B3
FAS
CFLAR
ValerylglycineHexanoylglycine
Isovalerylglycine
N-Butyrylglycine
Phenylacetylglycine
4-Fumarylacetoacetic-acid
GLYATL2
NRIP1
NMI
KAT2A
ZNF512B
DHX9
ELF3
FAM129B
DRAP1
VPS26A
GTF2B
MYH10
ACTN4
GRIN2B
ANG
RGN
PBX1
HDAC4 ACTN2
HNF4A
NR1H2
COIL
STAT5B
STAT6
GTF2A2
RBM48
TBP NR1I2
TAF9
HMGB1
GADD45G
RXRA
RNH1
STAT5A
PAX5
RXRB
NCOA6
THRA
TAF11
NCOR2
SMAD4
Androsterone
RFX1
UGT2B7
NAT8 FOXO3
NCOA1
VDR
MEF2A
PPARA
CEBPB
ESR2
TFE3 CENPJ
TAF1
CREG1
PSMA2 NAA10
NR1D2
TAF5
RRAS2
TPK1
Glutathione
GAMT
ESD
GATM
THTPA
ARG1
Dihydrotestosterone
HSD17B2
GSTT2
CYP11B2
Aldosterone
CYP8B1
Estriol
SRD5A1
Squalene
ACSS2
HMP19
AKR1D1HSD11B1
NR3C2
APOC1
ANXA5
Farnesyl-pyrophosphate
FDPS
Dimethylallylpyrophosphate
ADK
Isopentenyl-pyrophosphate
SUPT4H1
Propinol-adenylate
ITGB5 FDFT1
IDI1
ACSS3
ABCC1
Cortisone
FDX1
UGT2B28
11b-Hydroxyandrost-4-ene-3,17-dione
ABCC4
7a,12a-Dihydroxy-cholestene-3-one
Corticosterone
HSD17B7
GLO1 Cortisol
17-beta-Estradiol-3-glucuronide
CA1
7a-Hydroxy-cholestene-3-one
Androsterone-glucuronide
UGT2B17
GCKR
D-Maltose
SLC2A11
SLC5A9 Amylose
D-Glucose
GAA
SLC1A4
ETNPPL
N'-Formylkynurenine
D-Fructose
KHK
PYGM
SLC2A7
SLC2A8
AGL
GCK
B4GALT2
SLC2A4
GPD1
AKR1B1
GPD2
Maltotriose
TFAMGBE1
MCCC1CCNA2
MGAM
Dihydroxyacetone-phosphate
ALDOB
CTSA
D-Tagatose-1-phosphate
D-Xylulose-1-phosphate
CTBP2
HYPK
PSMD8
DDI2
TARS
PSMA1
ARHGAP32
NAA15
PDLIM1
Gluconolactone
IDNK
Gluconic-acid
PSMD3
Carbonic-acid
CA2
PCCB
CA6
MCCC2
CA3
NPDC1
SLC4A1
DAP3
CDT1
LPIN1
ANXA2
PURACDC23
PHB
IL1A
MCM6
SKP2
CDKN2A
ZNF420
ACACB
ZNF622
CDK7
CCNA1
ICT1
CA12
E2F6
MYBL2
FZR1
EID3
CNBP
GMNN
MCIDAS
CCNH
FTSJ1
GRSF1
CA9
NDN
EID2
MAGED2
HIST1H1B
ACLY
CDK6
E2F1
TFDP1
NDNL2
MAGEA1 USP26
RBL1
HOXA1
SPG7
TNFRSF1B
KRTAP5-9
FBXO2
VAT1
UBQLN2
LRCH4
TTC1
KRT17
KRT18
SEC24A
SLC25A1
KRT8
CHMP2A
HRAS
STAM2
TNK2
RNF103-CHMP3
MDFI
UBQLN4
PDE6D TOM1L1
PFKP
BACE1
AMPH
COX15
CTBP1CLTC
STAMBP
COMMD3-BMI1 FBXW5
IMMT
PDIA5
C8orf33
CLN3
LIMS1
ATP1A1
KIF23
EPN2
CEP135
ACO1
ZHX2 RALGDS
LDB2
6-Hydroxymelatonin
EHMT2
CYP2F1
ZC3H4
L-Malic-acid
QRSL1
GGA1
CRYZ
RASIP1
IGF2R
RALA
LGALS1
RNF11
MAN2B1
SASS6
WIZ
CBX6
RAB18
WRAP73
CBX8
ARF3
C11orf54
LASP1
GLYCTK
TRIP13
TNF
GSS
L-Asparagine
L-Formylkynurenine
GCLC
IDO2
L-Tyrosine
L-GlutamineL-Cysteine
3-Sulfinoalanine
CSAD
Cysteic-acid
SCPEP1
SLC38A3
4-Hydroxyphenylpyruvic-acidISOC1
SHMT1
L-Aspartic-acid
GCSH
PDIA4
CAD TAT
FCGR2B
Hypotaurine
NKX2-1
GUSB
ASNS
PAH
ABCC2
TTPA
PAG1
ACY3
GPT2
SLC36A1
Taurine
SLC38A5
AASS
PET112
SLC6A14
AADAT
4-Hydroxyproline
PHYKPL
CD22
MGMT
SEC14L2
TGM1
MDK
PTPN6
DDAH1
Naphthalene-epoxide
EPHX2
RMDN3
CYP1A2
PSEN1
POR
11,12-Epoxyeicosatrienoic-acid
ST13
CYP2E1
EPHX1
GSTT1
NOS3
Melatonin
Citrulline
5,6-Epoxy-8,11,14-eicosatrienoic-acid
ECSIT
CYP2C8
8,9-Epoxyeicosatrienoic-acid
COL6A2
CALR
KIR2DL3
FASN
NAGLU
CSE1L
HLA-A
PDIA3
CTTN
Pipecolic-acid
C20orf24
4-cis-Decenoyl-CoA
NUP93
FADH
trans-3-Hexenoyl-CoA
4,8-Dimethylnonanoyl-CoA
HACL1
Homocysteine
Putrescine
NUDT7
Hexanoylcarnitine
DECR2
2-Hydroxyphytanoyl-CoA
DECR1
SARDH
EHHADH
DMGDH
ACADM
trans-3-Decenoyl-CoA
trans,cis-Lauro-2,6-dienoyl-CoA
DHRS4
CRAT
HADH
ETFDH
SLC22A4
cis,cis-3,6-Dodecadienoyl-CoA
PEX3
HSD17B12
ACSM5
PHYH
DEGS1
Butyric-acid
CROT
3a,7a,12a-Trihydroxy-5b-24-oxocholestanoyl-CoA
Acetoacetyl-CoA
ECH1
HADHB
3-Oxooctanoyl-CoA
Phytanoyl-CoA
SLC25A20
PEX14 ACAD8
HSD17B4
ETFA
4,8-Dimethylnonanoyl-carnitine
Caproic-acid
Dimethylglycine
BHMT
ACADSB
BHMT2
IVD
Propionylcarnitine
L-Carnitine
PEX12
GSTK1
ACSM1
CLPP
PEX19
PEX5
CHDH
UBA5
ECI1
PIPOX
ABCD1
ABCD3
BCHE
Tetracosahexaenoyl-CoA
Docosa-4,7,10,13,16-pentaenoyl-CoA
DNAJC11
ETFB
Ergothioneine
BBOX1
IGHM
ABHD17A
PLIN3
HMGCR
HMGCL
ERLIN2
MUL1
NNMT
ZHX1
SYVN1
APPBP2
HOXD3
PDLIM7
CTSZ
HMGCS2
GRN
PDCD6IP
N-Acetylornithine
DHRS1
16-Hydroxy-hexadecanoic-acid
ME1
IKZF2
SLC25A10
ACY1
ADH5
ATF63-Hydroxy-3-methylglutaryl-CoA
NFYA
NFYB
MG(20:0/0:0/0:0)
Desmosterol
DHCR24
4,4-Dimethyl-5a-cholesta-8,24-dien-3-b-ol
4,4-Dimethylcholesta-8,14,24-trienol
DHCR7
Zymosterol-intermediate-2
ACP6
SGPL1
ENPP6
TM7SF2
LanosterinCYP51A1
MSMO1
NSDHL
O-Phosphoethanolamine
ETNK2
LGALS13
Glycerophosphocholine
UEVLD
SLC16A3
Sebacic-acidSLC32A1
UPB1
(R)-b-aminoisobutyric-acid
GALM
FMO5
N,N-Dimethylaniline
FMO3
Trimethylamine-N-oxide PPL
DYNC1I1
FMO4
Dimethylaniline-N-oxide
dCMP
AK3 GYS2
HPRT1
CMPK1
EIF4A2
Deoxyadenosine
MYO1B
UGP2
ATP6V1B2
FXR2
RABAC1
PACSIN1
TRIM16
CDC27
EMILIN1
CDH1
DSG2CTNND1
DSP
ABI1
CYFIP2
ZBTB33
NFATC4
NAPSAATP6V1H
GKAP1
FGGY
APIP
PCBD1
HNF1A
RAB33A
CDH5
JUP
FMR1
CYP4A11
RETSAT
MAOB
ALDH8A1
Beta-Alanine
ADH7
TTK
KAT7
KRT20
FABP4
ZBED1
CYP7B1
SULT2A1
Calcidiol
Vitamin-D3
TRIP6
HOXA9
RPS5
GART
ENPP1
3'-AMP
CMBL
FPGS
ATIC
GGH
PNP
RELB
NT5C1B
ALDH1L1
Adenine
Inosinic-acid
CRMP1
FABP5
PLBD1FBP1
FMO1 TNNT1
ARL6IP1
NT5C2
VIM
GLUL
NUDT18
ATP6V1B1 WDYHV1
PHGDH
3a,7a,12a-Trihydroxy-5b-cholestanoyl-CoA
FAAH
27-Hydroxycholesterol
PLIN2
Oleic-acid
Docosahexaenoic-acid
PRDX4
FABP1
Uridine-diphosphate-glucose
10-Formyltetrahydrofolate
ACP2
SRM
MTAP
GYG2
Dihydrofolic-acid
5'-Methylthioadenosine
Dephospho-CoA
RDH13
UROC1
2-Methyl-3-oxopropanoic-acid
Ureidopropionic-acid
SLC16A1
Tyramine
RDH16
AACS
HAL
Tryptamine
DPYS
ADH6
DPYSL2
DDC
ALDH1B1
3,4-DihydroxymandelaldehydeIndoleacetaldehyde
FECH
Vitamin-A
RANBP6
HSPB1
ALDH2
UNG
TNPO1
3-Hydroxybutyric-acid
MAOA
CTH
IGSF21
9-cis-Retinal
Hexadecanedioic-acid
2-Hydroxybutyric-acid
ANXA3
(S)-3-Hydroxybutyric-acid
FABP2
ACP5
3-Methoxytyramine
BDH2
Urocanic-acid
DPYSL3
ACSL5
2-Ketobutyric-acid
ETHE1
TNIK
SLC35F6
MAPKAPK3
ANXA4
ABAT
ALDH1A1
SEPHS1
BPGM
RPP14
Normetanephrine
Homovanillin
SLC16A7
Biotin
L-Lactic-acid ACAT2
ALDH6A1
5-Hydroxy-L-tryptophan
MME
Acetoacetic-acid
ALDH3A2
ADHFE1
HAO1
Glycylproline
L-Serine
L-Lysine
Hydroxypyruvic-acid
LDHD
Glycyl-L-leucine
PKLR
NF2
6-Phosphogluconic-acid
PGM3
ARCN1 DAK
NAGK
Phosphoenolpyruvic-acid
N-Acetyl-D-mannosamine-6-phosphatePC
ACAT1
GNMT SLC9A3R1
SHMT2
Allantoin
GCAT
L-Kynurenine
Glyceric-acid
URAD
SLC7A2
NAGA
FBXO6
SLC2A1
PCK1
TARBP2 PAICS
COL6A3
Oxalacetic-acid
HLA-C
COPG1
TAP1
SORD
D-Ribulose-5-phosphate
SPTLC1
SMS
GRHPR AGXT
N-Acetyl-D-Glucosamine-6-Phosphate
NPEPPS
N-Acetyl-D-glucosamine
PRKCSH
NDRG1
PGD
NANS
GLS2
CNDP2GOT1
DLD
LDHA
PEPD
KYNU
(S)-2-amino-6-oxohexanoate
Glycine
L-Alanine
ALDH7A1
SLC3A1
CCBL2
SLC15A1
AGXT2
Glyoxylic-acid
2. Glucose and
glycogen metabolism
1. Amino acid and
pyruvate metabolism
11. Transcription
10. ECM organization
13. Bile acid metabolism
9. Cell-cell interactions
5. Apoptosis
6. Histidine, tyrosine, 
and retinol metabolism 
4. Unfolded protein response
Ketone body metabolism3. Endocytosis
12. Xenobiotic and 
drug metabolism
20. N/A
7. Fatty acid/lipid 
oxidation
15. Mitosis
14
16
8
17
18
19
Protein
Metabolite
Transcription factor
Receptor
Terminal up in HFD
Terminal down in HFD
Protein-protein
Protein-metabolite
14. Steroid biosynthesis
16. Steroid metabolism
8. Arginine/proline metabolism, TCA cycle
17. Cholesterol, steroid, and lipid metabolism 
18. Folate, purine/pyrimidine metabolism
19. Monoxygenase activity
Figure 4. Multi-omic PCSF Model Uncovers Features of Hepatic Insulin Resistance
The full PCSFmodel includes 398 terminal nodes and 509 predicted Steiner nodes connected by 2,365 interactions.We divided the solution into 20 sub-networks
and highlight the specific biological processes containedwithin these. Colored nodes (red or blue) represent terminal nodes, gray nodes represent Steiner nodes,
and shapes indicate node types (proteins, metabolites, transcription factors, or receptors).
See also Figures S5 and S6.
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Liver Tissue Analysis Confirms Global Alterations in
Hepatic Processes Identified by the PCSF Model
The network results imply roles for unexpected processes
related to diet-induced insulin resistance. To test these predic-
tions, we performed imaging studies on frozen liver sections
from CD and HFD mice. First, we tested the prediction that
HFD livers would display altered cell-cell interactions and overall
structural deficiencies. We stained liver sections for Zo1, a cyto-
plasmic membrane protein of intercellular tight junctions, and
cytokeratins 8 and 18, which are dimerized intermediate fila-
ments present in epithelial cells that help maintain cellular struc-
tural integrity. Using DAPI staining to identify nuclei, we found
cellular boundaries and tight junctions around bile ducts in the
liver of CD-fed mice. By contrast, tight junctions and structure
near bile ducts of HFD liverswere highly disorganized (Figure 6A).
In larger fields of view, we saw highly structured hepatocyte bor-
ders and normal architecture in CD livers (Figure 6B). In contrast,
HFD livers displayed irregular cytokeratin 8/18 staining, with few
discernable cell borders, indicating overall disruption of the he-
patic tissue architecture in response to the long-term dietary
challenge.
We also tested the prediction that HFD livers would display
abnormal bile acid handling by staining liver sections for collagen
and bile/bilirubin (Figure 6C). As expected, we found no bile acid
leakage or accumulation in CD livers. However, we observed sig-
nificant bile accumulation in HFD livers. These results corrobo-
rate our prediction that HFD livers possess defects in bile acid
maintenance and are consistent with the altered cellular struc-
tures we found surrounding the bile ducts of HFD-fed mice.
Finally, we tested whether consumption of an HFD enhances
the number of hepatocytes undergoing apoptosis in the liver.
We used DAPI and terminal deoxynucleotidyl transferase dUTP
nick-end labeling (TUNEL) to assess the number of apoptotic
cells. The fraction of TUNEL-positive cells in CD livers was very
low (1%), whereas HFD livers displayed regions of high TUNEL
positivity (as high as 37%; Figure 6D). While not prevalent in all
regions, overall apoptosis was higher in HFD samples (Figure 6D,
p = 0.014). Thus, we show here evidence for enhanced hepato-
cyte apoptosis as a feature of HFD-induced hepatic insulin
resistance.
DISCUSSION
Weundertook a large-scale integrative systems analysis of HFD-
induced hepatic insulin resistance. We used ChIP-seq and
mRNA-seq to interrogate epigenomic regulation and transcrip-
tion, untargeted shotgun proteomics to quantify >6,000 hepatic
proteins, and metabolomics to profile nearly 400 small-molecule
species. Using a network approach, we integrated these data-
sets and highlighted major biological processes perturbed by
HFD. The algorithm also incorporated disease-relevant proteins
and metabolites from the interactome that were either not
measured or found to be differentially expressed in our omic
data. We validated several high-level model predictions by
examining mouse livers for markers of specific physical features
and biological processes. We found that HFD consumption per-
turbs hepatic architecture, disrupts bile acid handling, and en-
hances hepatocyte apoptosis.
The liver is a major contributor to overall glycemic regulation.
Indeed, insulin-stimulated clearance of blood glucose is medi-
ated, in part, by the inhibition of hepatic gluconeogenesis (Pilkis
and Granner, 1992) and consumption of an HFD causes hepatic
insulin resistance, which disrupts this process (Pilkis and Gran-
ner, 1992). As expected, we found that the HFD feeding in
mice caused obesity, insulin resistance, and impaired glucose
homeostasis. These features were accompanied by HFD-
induced changes in >2,000 genes, 362 global proteins, and 96
metabolites. We note that these findings derive from molecules
measured from whole-liver extracts. While hepatocytes repre-
sent the dominant cell type in liver tissue, hepatic stellate cells,
vascular endothelial cells, and various immune cells do, indeed,
influence liver function and molecular concentrations. Thus, our
results must be interpreted within this framework.
We used a motif regression procedure that incorporated epi-
genomic, transcriptomic, and motif data to identify transcrip-
tional regulators relevant to insulin resistance, identifying 272
significant factors. Several of these top predictions are consis-
tent with factors identified in a prior study that used different epi-
genomic techniques to find regulatory regions (Leung et al.,
2014). Interestingly, both our study and theirs did not observe
many changes in histone modification levels between the diets,
despite significant gene expression changes. An advantage of
our integrative modeling approach is that, even if a pathway is
not detected as changing by one experimental method, it may
emerge in the network based on evidence from other types
of data.
To integrate all the omic datasets we collected, we built on the
established PCSF network modeling approach (Tuncbag et al.,
2013, 2016). The PCSF method is not required to include all
omic data yet is capable of introducing predicted nodes that
are critical for establishing connections between the detected
molecules. PCSF networks are generally much smaller and
more tractable than solutions derived from more naive methods
and reveal interpretable sub-networks enriched in specific bio-
logical processes and pathways. Here, we have significantly
expanded the scope of the PCSF methods by adding physical
associations of proteins and metabolites to the protein-protein
interactome. This unified approach allowed us to capture a wider
range of biological pathways and processes relevant to insulin
resistance. We also used several strategies to improve the accu-
racy of our networks. Prior studies have noted that network
methods can be biased toward highly studied proteins that
appear as ‘‘hubs’’ in the interactome (Paull et al., 2013). To
Table 1. PCSF Model Terminal Node Inclusion Statistics
Terminal Type
Number of
Terminals
Number Included
in Final Model % Included
Metabolites 83 63 75.9
Global proteins 329 301 91.5
Transcription factors 272 34 12.5
This table shows numbers of terminals (input data) supplied to the PCSF
algorithm for metabolite, global protein, and transcription factor data
types. The numbers of terminals for each data type present in the final
solution are shown, along with percentages.
See also Figure S5.
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reduce this bias, we applied a soft penalty to highly connected
nodes to discourage their inclusion while still allowing for their
use when particularly necessary. We additionally tested our net-
works for robustness to noise and assessed the specificity of
network nodes to our system.
Our integrated approach can identify many different types
of links among the omic data. We found pathways that
were largely dominated by proteomic data (e.g., cell-cell interac-
tions, ECM, apoptosis) but also found several sub-networks
almost entirely composed of protein-metabolite connections
(e.g., bile acid metabolism and glucose metabolism). The inclu-
sion of direct metabolomic data along with protein-metabolite
interactions was critical to capturing, for instance, relevant con-
nections among differential proteins whose roles are best ex-
plained in the context of metabolic processes (e.g., GCK and
CYP7B1).
Increasingly, systems biology and omic approaches are being
recognized for their utility to the study of insulin resistance and
type 2 diabetes (Zhao et al., 2015). To date, however, few studies
have formally integrated multiple types of omic data in these
contexts, with even fewer including metabolomics. Prior studies
attempting such joint analyses used correlative statistical rou-
tines (Miraldi et al., 2013; Oberbach et al., 2011), methods that
overlay proteomic and metabolomic data onto genome-scale
metabolic reconstructions (Yizhak et al., 2010), or methods
that map metabolomic and transcriptomic data onto known
Figure 5. PCSF Sub-networks for Select
Biological Processes
We highlight PCSF model sub-networks that are
enriched in extracellular matrix (ECM, top left), cell-
cell interactions (top right), and apoptosis (bottom
left). Note that node specificities should only be
compared within sub-networks, as overall panel
sizes differ for clarity. TF, transcription factor.
See also Figure S7.
pathway and transcriptional regulatory
data without identifying high-confidence
sub-networks (e.g., the CircadiOmics
resource) (Eckel-Mahan et al., 2013). Our
approach goes well beyond these previ-
ous methods by incorporating multiple
data types from the same samples, allow-
ing for interactions that occur outside
well-established signaling or metabolic
pathways, and using advanced ap-
proaches to reduce the possible interac-
tion space to only the most relevant
connections, thus increasing the inter-
pretability of results and providing clear
guidance for designing experiments.
Our model uncovered a highly intercon-
nected network associated with the insu-
lin-resistant state in the liver. We pre-
dicted that changes to the ECM, cell-cell
interactions, and overall hepatic architec-
ture are features of insulin resistance.
Subsequent experiments confirmed that the overall structure
of HFD mouse livers is highly disrupted, especially near bile
ducts. Consistent with this observation, we also found enhanced
bile acid leakage (cholestasis) into the tissue of HFD-fed
mouse livers. These structural abnormalities likely also
contribute to the increased apoptosis that we observed in
insulin-resistant livers. The link between hepatic ECM and
architectural structural remodeling with insulin resistance has
been studied sparingly (Williams et al., 2015a). In one study,
tail-vein injection of HFD-fed mice with a hydrolase for
hyaluronan, an ECM component, reduces features of muscle
and liver insulin resistance (Kang et al., 2013). Moreover,
integrin-a1-subunit-deficient mice (Itga1/) fed an HFD display
reduced fatty liver content but also severe hepatic insulin resis-
tance, compared to wild-type HFD-fed controls (Williams et al.,
2015b).
The hepatic structural changes detected in HFD-fed mice may
be related to changes in apoptosis. Crosstalk between proteins
relevant to insulin resistance and hepatocellular injury, including
tumor necrosis factor (TNF), nuclear factor kB (NF-kB), and JNK,
has been proposed as a potential driver of apoptosis in the liver
(Schattenberg and Schuchmann, 2009). Indeed, apoptosis is
associated with severe hepatocellular injury and steatohepatitis
(Guicciardi and Gores, 2005). Here, we report increased hepatic
apoptosis in HFD-fed mice. This increased hepatic apoptosis
may be related to dysregulation of the hepatobiliary system
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(Wang, 2014) and promotes low-grade inflammation and hepatic
insulin resistance.
Previous studies have associated changes in liver architecture
with late stages of hepatic steatosis that lead to non-alcoholic
steatohepatitis and the development of hepatic fibrosis (Rama-
chandran andHenderson, 2016). The results of the present study
demonstrate that defects in hepatic architecture precede
fibrosis and can be detected in early stages of the response to
the consumption of a HFD. It is likely that these early changes
in hepatic architecture contribute to the long-term development
of hepatic dysfunction.
To summarize, we undertook a large-scale systems biology
approach to study HFD-induced hepatic insulin resistance. We
integrated multiple types of omic datasets into a network model
that uncovered altered biological processes associated with the
condition. By incorporating metabolites into the protein-protein
interaction network, we were able to identify a wide range of mo-
lecular changes. We validated several global predictions from
our network model with additional experiments and highlighted
components relevant to the hepatic response to HFD consump-
tion. The pathways and processes we found to be altered by
HFD present a wide range of directions for future research. Our
methods are easily applicable to other large-scale omic analyses
of diverse biological systems and diseases.
CB
D
A Figure 6. Hepatic Imaging Validates Global
PCSF Model Predictions
(A) HFD-induced changes in tight junction struc-
ture near bile ducts (BD) as assessed by cytoker-
atin 8/18 (CK8/18) and Zo1 staining. Scale bars: for
CD, 6 mm; for HFD, 8 mm.
(B) CK8/18 staining revealed overall hepatic
architectural defects in HFD samples. Scale bars,
48 mm.
(C) We observed enhanced bile acid leakage in
HFD livers stained for collagen and bile/bilirubin
compared to CD livers. Scale bars, 100 mm.
(D) TUNEL imaging revealed enhanced regions
of hepatocyte apoptosis in HFD samples. Points
on graph represent values from individual fields
of view (ns = 9, 7, and 4 for HFD livers; ns = 4, 5,
and 5 for CD livers), and bars indicate overall
TUNEL-positive fraction (total TUNEL-positive
cells over total cells) based on all fields of view.
We found that the overall difference in TUNEL
staining between the diets is statistically sig-
nificant by two-tailed t test (p = 0.014). Scale bars,
40 mm.
EXPERIMENTAL PROCEDURES
Animals
We obtained male C57BL/6J mice (stock number
000664) from the Jackson Laboratory. All mice
were housed in a specific pathogen-free facility
accredited by the American Association for
Laboratory Animal Care. We fed the mice either
(1) a standard CD (Prolab Isopro RMH 3000,
Purina) for 24 weeks or (2) 8 weeks of standard
CD followed by 16 weeks of HFD (S3282, Bio-
serve). We measured fat and lean mass noninva-
sively using 1H-MRS (Echo Medical Systems).
We euthanized all mice at 24 weeks after an overnight fast and froze the
livers prior to removal using clamps cooled in liquid nitrogen. The frozen livers
were then pulverized into a powder using a CryoPREP impactor (Covaris).
We prepared aliquots of pulverized liver for all samples for subsequent
analyses. All experiments were carried out in accordance with guidelines for
the use of laboratory animals and were approved by the Institutional Animal
Care and Use Committees (IACUCs) of the University of Massachusetts Med-
ical School.
Glucose and Insulin Tolerance Tests
We performed glucose and insulin tolerance tests by intraperitoneal injection
ofmicewith glucose (1 g/kg) or insulin (1.5 U/kg) usingmethods described pre-
viously (Sabio et al., 2008).
Immunoblot Analysis
Protein extracts from pulverized liver were prepared in Triton lysis
buffer (20 mM Tris [pH 7.4], 1% Triton X-100, 10% glycerol, 137 mM NaCl,
2 mM EDTA, 25 mM b-glycerophosphate, 1 mM sodium orthovanadate,
1 mM PMSF, and 10 mg/mL each of aprotinin and leupeptin). We quan-
tified protein content by the Bradford method (Bio-Rad). Standard tech-
niques were used to separate cell extracts (15–80 mg protein) by SDS-
PAGE for immunoblot analysis using antibodies from Cell Signaling
Technology (AKT and pSer473-AKT). The primary antibodies were detected
by incubation with anti-mouse or anti-rabbit immunoglobulin G (IgG)
conjugated to infrared dyes (IRDye, LI-COR Biosciences). We detected im-
mune complexes using the Odyssey Infrared Imaging system (LI-COR
Biosciences).
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mRNA-Seq and Analysis
We prepared mRNA-seq libraries from three CD and three 16-week HFD
mouse livers using the TruSeq RNASample Prep Kit v.1 (Illumina). This was fol-
lowed by 180 ± 25 bp insert size selection using 2% agarose gel electropho-
resis. WemultiplexedmRNA-seq libraries and paired-end sequenced samples
for 40–50 bp on an Illumina Hi-Seq 2000 machine. On average, we obtained
20–30 million raw paired-end sequencing reads. Read alignment, gene
quantification, and differential analysis details are provided in the Supple-
mental Information. Briefly, we aligned reads to the mm9 genome using
TopHat (v.1.4.0) (Trapnell et al., 2009) and used DESeq2 (v.1.0.18) (Love
et al., 2014) to perform differential expression analyses. We considered a
gene to be differentially expressed if it possessed an absolute log2 fold change
between conditionsR 0.5 and an FDR-adjusted p value (q value)% 0.05 and
was expressed in at least one tested condition (i.e.,R0.1 fragments per kilo-
base of transcript per million mapped reads [FPKM]).
ChIP-Seq and Analysis
Histone modification ChIP experiments were performed using the MAGnify
Chromatin Immunoprecipitation System Kit (Life Technologies, Carlsbad,
CA), with antibodies against H3K4me1 (17-676, Millipore), H3K4me3 (17-
614, Millipore), and H3K27ac (ab4729, Abcam, Cambridge, MA). ChIP-seq
libraries were constructed using the NEBNext DNA Library Prep Master Mix
Set for Illumina (New England Biolabs, Ipswich, MA, USA) and sequenced
on an Illumina Hi-Seq 2000 machine. We aligned raw reads using Bowtie
(v.0.12.7) (Langmead, 2010) and performed peak calling using model-based
analysis of ChIP-seq (MACS) (v.1.4.0rc2) (Zhang et al., 2008) against an IgG
control. We considered significant MACS peaks to be those possessing a
p value < 1e6 and an FDR < 10%. We also performed differential peak ana-
lyses between conditions; details of these methods are provided in the Sup-
plemental Information. We considered regions possessing an FDR-corrected
p value < 0.05 as significant.
Global Proteomics
We collected global proteomic data from four CD and four 16-week HFD
mouse livers using mass-spectrometry-based methods. Full details of the
experimental methods and statistical analyses are provided in the Supple-
mental Information. We deemed proteins possessing an FDR < 0.1 between
CD and HFD livers as differentially expressed.
Metabolomics and Analysis
We extracted and split samples (6 independent livers per condition, per
Metabolon recommendations for appropriate statistical power) into equal
parts for analysis on gas chromatography-mass spectrometry (GC-MS) and
liquid chromatography-tandem mass spectrometry with electrospray ioniza-
tion in positive and negative ion modes (LC-MS/MS, ESI ±). A total of 381
metabolites were identified and quantitated. We imputed missing values
with a k-nearest-neighbors procedure (k = 10), normalized samples according
to the procedure in Anders and Huber (2010), and tested for differences using
two-tailed t tests, correcting p values for multiple hypotheses. We observed
strong intra-sample correlations between CD (Pearson’s r > 0.923) and HFD
(r > 0.85) replicate abundances (Figure S2C). Metabolites possessing an
FDR < 0.1 were deemed significant. The raw data and differential expression
results for these data are provided as Data S2.
Motif Regression Analysis
General methods are described in the main text. Full details of these proced-
ures are provided in the Supplemental Information.
Prize-Collecting Steiner Forest Modeling
Full details of all methods related to the prize-collecting Steiner forest (PCSF)
modeling approach are included in the Supplemental Information. Briefly, the
prize-collecting Steiner forest (Tuncbag et al., 2013, 2016) aims to find a forest
F(VF, EF) from the graph G(V, E, c(e), p(v)), with nodes V, edges E, edge costs
c(e)R 0, and node prizes p(v) for v ˛ V, that minimizes the objective function:
PCSFðFÞ=
X
v;VF
pðvÞ+
X
e˛EF
cðeÞ+u,k;
where k represents the number of trees in the forest, u represents a tuning
parameter that influences the number of trees included in the final forest, and:
pðvÞ= b,poðvÞ  m,degreeðvÞn:
The b parameter scales the importance of node prizes versus edge costs.
We used a ‘‘negative prize’’ scaling scheme to each node in G proportional
to its degree, or number of connections in the interactome, to reduce the influ-
ence of highly connected, well-studied nodes. The parameter m scales the in-
fluence of the negative prizes, and the exponent n allows for non-linearity in the
scaling. We built a combined protein-protein and protein-metabolite interac-
tome using v.13 of the iRefIndex database (Razick et al., 2008) for protein-pro-
tein interactions (scored with the MIscore system; Villaveces et al., 2015) and
v.3.6 of the HMDB (Wishart et al., 2013), supplemented with manually curated
interactions from the human metabolic reconstruction Recon 2 (v.3) (Thiele
et al., 2013), for protein-metabolite interactions. We used a community clus-
tering algorithm (Blondel et al., 2008) to break the full PCSF model into smaller
sub-networks and visualized all networks with Cytoscape (Shannon et al.,
2003).
Liver Tissue Section Analysis and Imaging
Histology was performed using liver fixed in 10% formalin for 24 hr, dehy-
drated, and embedded in paraffin. Dewaxed and rehydrated sections
(7 mm) were cut and stained for bile acids (product #KTHBI, American Master
Tech Scientific) or with H&E (American Master Tech Scientific). Sections
(7 mm) prepared from liver frozen in O.C.T. Compound (Tissue-Tek) were
stained with oil red O (Sigma) to visualize lipid droplets. We acquired images
using a Zeiss Axiovert 200M microscope. Liver architecture was assessed
using frozen sections fixed with 4% paraformaldehyde and stained with an
antibody to cytokeratin 8 (TROMA-1-c, Developmental Studies Hybridoma
Bank [DSHB], University of Iowa). Immune complexes were detected using
anti-rat Ig conjugated to Alexa Fluor 488. Liver damage was assessed in
frozen (7-mm) sections fixed with cold ethanol/acetic acid (2:1) using an
in situ cell death kit (Roche). Bile duct architecture was assessed in frozen
(7-mm) sections fixed with cold methanol by staining with antibodies to
Zo-1 (sc-10804, Santa Cruz Biotechnology) and cytokeratin 8/18 (sc-
52325, Santa Cruz). Immune complexes were detected using anti-mouse
Ig conjugated to Alexa Fluor 488 and anti-rabbit Ig conjugated to Alexa Fluor
633 (Life Technologies). DNA was detected by staining with DAPI (Life
Technologies). Fluorescence was visualized using a Leica TCS SP2 confocal
microscope equipped with a 405-nm diode laser.
TUNEL Imaging Analysis
We used CellProfiler (v.2.1.1) (Carpenter et al., 2006) with a custom-built anal-
ysis pipeline frommodules included in the program to analyze TUNEL images.
All images across CD and HFD samples were analyzed in a single run of
the program at the same settings. Pipeline details are described in the
Supplemental Information. The TUNEL-positive percentage per field of view
was calculated as the number of positive nuclei over the total. For each
liver, we calculated a single TUNEL-positive fraction by dividing the total
number of TUNEL-positive nuclei by the total number of nuclei across all
fields of view (ns = 9, 7, and 4 for HFD livers; ns = 4, 5, and 5 for CD livers).
We used a two-tailed t test to test for statistical significance between CD
and HFD livers.
Clustering and Enrichment Analyses
All hierarchical clustering analysis was done with the clustergram function in
MATLAB with Euclidean distance and average linkage. For enrichment ana-
lyses, we used custom MATLAB code, implementing the hypergeometric dis-
tribution for enrichment p value calculations and used theBenjamini-Hochberg
FDR procedure to correct for multiple hypotheses. In general, an FDR < 0.1
was deemed significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the mRNA-seq and ChIP-seq raw and processed
data reported in this paper is GEO: GSE77625.
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